Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$0.76 USD
0.00 (-0.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.75 -0.01 (-1.19%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNGO 0.76 0.00(-0.28%)
Will BNGO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNGO
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Other News for BNGO
3 Contrarian Investments to Make Now for Massive Upside Potential
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Bionano Genomics announces publication on OGM's structural variation detection
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Bionano Genomics enters partnership with Diagens